Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1433-7339
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial ; volume:21 ; number:8 ; day:19 ; month:5 ; year:2013 ; pages:2341-2349 ; date:8.2013
Supportive care in cancer ; 21, Heft 8 (19.5.2013), 2341-2349, 8.2013
- Creator
-
Peterson, Mary E.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00520-013-1826-3
- URN
-
urn:nbn:de:101:1-2019101622312274102097
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Peterson, Mary E.
- SpringerLink (Online service)
Other Objects (12)
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
Rat Models of Hormone Receptor-Positive Breast Cancer
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
Rat Models of Hormone Receptor-Positive Breast Cancer
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
Rat Models of Hormone Receptor-Positive Breast Cancer
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer